ImmunityBio tries again in papillary bladder cancer
And the company says it won’t need to carry out another trial.
J&J claims another second-line Tecvayli win
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Syndax switches first-line plans
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
ASH 2025 – J&J’s multiple myeloma juggling act
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
ASH 2025 – Regeneron’s Lynozyfic shows front-line promise
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
ASH 2025 – Kura seeks further safety edge
The company will try to get the Komzifti QTc prolongation warning removed.
J&J tries to outdo Tecvayli
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
